EBV (LMP2)
Online Inquiry
| CAT# | PPO-H021 |
| Application | T-cell assays, Immune monitoring, Antigen specific T-cell stimulation, T-cell expansion, Cellular immune response |
| Purity | >70% (HPLC-MS) |
| Areas of Interest | Infection, Cancer, Hodgkin's lymphoma, Burkitt's lymphoma, Nasopharyngeal carcinoma, Dermatomyositis, Systemic lupus erythematosus, Rheumatoid arthritis, Sj?gren's syndrome, Multiple sclerosis |
| Size | 1 vial containing 15 nmol ( 25μg) per peptide |
SwissProt ID | P13285 |
Format | Freeze dried in amber type glass vial |
NumberOfPeptides | 122 |
Organism | Epstein-Barr virus (HHV-4) |
Specifications | Peptide scan (15mers with 11 aa overlap) |
Protein Length | 497 |
Protein Name | Latent membrane protein 2 (LMP2) |
References | 1."T-cell Therapy for EBV-Associated Nasopharyngeal Carcinoma: Preparative Lymphodepleting Chemotherapy Does not Improve Clinical Results". Secondino et al., Ann. Onc. (2012)
2."Expansion of T Cells Targeting Multiple Antigens of Cytomegalovirus, Epstein – Barr Virus and Adenovirus to Provide Broad Antiviral Specificity After Stem Cell Transplantation". Hanley et al., Cytotherapy (2011) |
Write a review
Ask a question
My Review for EBV (LMP2)
Required fields are marked with *
×
Ask a Question for EBV (LMP2)
Required fields are marked with *
×
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
